MDT

85.63

-0.57%↓

113.17

+0.6%↑

VEEV

175.84

-1.21%↓

HQY

82.59

+1.93%↑

CSBR

5.59

-1.58%↓

MDT

85.63

-0.57%↓

113.17

+0.6%↑

VEEV

175.84

-1.21%↓

HQY

82.59

+1.93%↑

CSBR

5.59

-1.58%↓

MDT

85.63

-0.57%↓

113.17

+0.6%↑

VEEV

175.84

-1.21%↓

HQY

82.59

+1.93%↑

CSBR

5.59

-1.58%↓

MDT

85.63

-0.57%↓

113.17

+0.6%↑

VEEV

175.84

-1.21%↓

HQY

82.59

+1.93%↑

CSBR

5.59

-1.58%↓

MDT

85.63

-0.57%↓

113.17

+0.6%↑

VEEV

175.84

-1.21%↓

HQY

82.59

+1.93%↑

CSBR

5.59

-1.58%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

14.28 1.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.96

Max

14.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	5.283 57.05
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+44.82% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.5B
Ankstesnė atidarymo kaina	12.93
Ankstesnė uždarymo kaina	14.28

Naujienos nuotaikos

By Acuity

50%

169 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-30 23:15; UTC

Svarbiausios naujienos

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026-03-30 22:36; UTC

Svarbiausios naujienos

Australian Government Rules Out Boots on the Ground in the Middle East

2026-03-30 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026-03-30 21:00; UTC

Uždarbis

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026-03-30 20:15; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026-03-30 23:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026-03-30 23:36; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026-03-30 23:12; UTC

Rinkos pokalbiai

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026-03-30 22:49; UTC

Rinkos pokalbiai

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026-03-30 22:44; UTC

Rinkos pokalbiai

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026-03-30 22:43; UTC

Rinkos pokalbiai

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026-03-30 22:42; UTC

Rinkos pokalbiai

South32 Should Go for Growth, Says New Bull -- Market Talk

2026-03-30 22:18; UTC

Rinkos pokalbiai

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026-03-30 22:05; UTC

Rinkos pokalbiai

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026-03-30 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026-03-30 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026-03-30 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026-03-30 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026-03-30 21:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 21:25; UTC

Rinkos pokalbiai

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026-03-30 21:03; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026-03-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-30 20:09; UTC

Uždarbis

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026-03-30 20:00; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

44.82% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 44.82%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

169 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.